Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

99 results about "Replication cycle" patented technology

Within eukaryotes, DNA replication is controlled within the context of the cell cycle. As the cell grows and divides, it progresses through stages in the cell cycle; DNA replication takes place during the S phase (synthesis phase).

Methods and products for evolving genes

PCT designated stage expiredWO2024240906A1Virus peptidesTransferasesBiotechnologyDNA replication
The invention relates to cells comprising orthogonal DNA replication machinery, linear plasmids that may be replicated by said machinery, uses of said cells and said linear plasmids, methods of maintaining linear plasmids in cells, methods of evolving sequences of interest, and methods of making polypeptides or nucleic acids. The invention also relates to error-prone DNA polymerases, nucleic acids encoding said polymerases, and uses thereof.
Owner:UNITED KINGDOM RESEARCH AND INNOVATION

Non-integrating viral delivery system and methods related thereto

A non-integrating viral delivery system is disclosed. The system includes a viral carrier, wherein the viral carrier contains a defective integrase gene; a heterologous viral episomal origin of replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest.
Owner:AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC

Application of VPS35 inhibitor in preparation of Zika virus infection resisting medicine

The invention belongs to the field of biological medicines, and discloses an application of a VPS35 inhibitor in preparation of Zika virus infection resistant drugs, the VPS35 inhibitor comprises at least one of the following two substances: I: a substance for inhibiting VPS35 gene expression in host cells; and II: a substance for inhibiting the retrograde transport function of the VPS35 protein in the host cell. The invention finds that the VPS35 protein is an important host factor of the replication period of the Zika virus for the first time, and a Zika virus infection model system verifies that the replication of the Zika virus in the host cell can be inhibited by inhibiting the expression of the VPS35 gene in the host cell or inhibiting the retrograde transport function of the VPS35 protein. Compared with traditional drugs targeting Zika virus protein, the VPS35 inhibitor provided by the invention targets host factors, is more difficult to induce Zika virus drug resistance, and has more lasting treatment potential.
Owner:WEIFANG MEDICAL UNIV

Anti-viral and anti-tumoral compounds

Disclosed herein are prokaryotic homologs of viperin (pVips), and nucleotide and nucleoside analogs produced from pVips. These nucleotide and nucleoside analogs stop nucleotide chain synthesis and provide host cells with resistance to viral infections by targeting actively replicating viral genome. Further, these nucleotide and nucleoside analogs decrease DNA replication in malignant cells. Further disclosed are methods of identifying pVips, and nucleotide and nucleoside analogs produced thereof.
Owner:YEDA RES & DEV CO LTD

Method for enhancing multiplication capacity of umbilical cord mesenchymal stem cells and application

The invention relates to the field of cell engineering and gene engineering, in particular to a method for enhancing the multiplication capacity of umbilical cord mesenchymal stem cells and application. The expression or activity of the STN1 gene in the umbilical cord mesenchymal stem cells is reduced through an accelerant, and the umbilical cord mesenchymal stem cells with enhanced multiplication capacity are obtained. By knocking down the hUC-MSCs of STN1, the proliferation speed of the hUC-MSCs is higher, DNA replication is more active, the clone formation ability is higher, and the aging proportion of the hUC-MSCs can be remarkably reduced.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +1

Application of antibacterial peptide with antifungal activity

The invention relates to the technical field of antibacterial peptides, in particular to application of an antibacterial peptide with antifungal activity, the antibacterial peptide is Jelleine-Ic, and the antifungal activity, the antibiofilm activity and the action mechanism of the Jelleine-Ic on candida albicans are disclosed. The Jelleine-Ic has a very strong antifungal activity on candida albicans, and the Jelleine-Ic has a very strong antifungal activity on The integrity of cell walls of the candida albicans is destroyed, and the permeability of cell membranes of the candida albicans is enhanced. Besides, Jelleine-Ic interacts with DNA when entering fungal cells, expression of genes participating in DNA replication and repair is affected, generation of active oxygen in the cells is induced, and death of the fungal cells is accelerated. According to the results, the Jelleine-Ic can effectively inhibit the growth of candida albicans and has the potential of treating fungal infection.
Owner:ANHUI AGRICULTURAL UNIVERSITY

Methods and products for evolving genes

The present invention relates to cells comprising an orthogonal DNA replication machine, linear plasmids replicable by said machine, uses of said cells and said linear plasmids, methods of maintaining linear plasmids in cells, methods of evolving sequences of interest, and methods of preparing polypeptides or nucleic acids. The invention also relates to error-prone DNA polymerases, nucleic acids encoding said polymerases and uses thereof.
Owner:UNITED KINGDOM RESEARCH AND INNOVATION

Enhancement of nucleic acid polymerization by aromatic compounds

The present invention relates to compounds, methods and compositions for improving nucleic acid polymerization, including DNA replication by in vitro primer extension to produce polymers for use, for example, in nanopore-based single-molecule sequencing of DNA templates. The nucleic acid polymerase reaction composition has a polymerization enhancing moiety that allows for enhanced activity of DNA polymerase with nucleotide analogs, resulting in increased length of primer extension products for sequencing applications.
Owner:F HOFFMANN LA ROCHE & CO AG

Error-prone dnaps for orthogonal DNA replication

PCT designated stage expiredWO2024249634A2EnzymesDNA preparationBase JExperimental laboratory
An accessible experimental approach for compressing long-term gene evolution to laboratory timescales allows for the rapid evolution of new biomolecular functions and for the direct observation of extensive adaptation and divergence followed by inference of structural, functional, and environmental constraints for any selectable gene. An orthogonal DNA replication system employing error-prone DNA polymerases durably hypermutates chosen genes at a rate of >10-4 substitutions per base in vivo. When used to evolve a conditionally essential maladapted enzyme, adaptation rapidly occurred and thousands of unique multi-mutation sequences were obtained with many pairs >60 amino acids apart (>15% divergence), revealing known as well as unexpected factors influencing enzyme adaptation. The fitness of evolved sequences was not predictable by advanced machine learning models trained on natural variation.
Owner:RGT UNIV OF CALIFORNIA

Non-integrating viral delivery system and methods related thereto

A non-integrating viral delivery system is disclosed. The system includes a viral carrier, wherein the viral carrier contains a defective integrase gene; a heterologous viral episomal origin of replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest.
Owner:AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC

Application of 4-hydroxyderrisin in preparation of anti-influenza virus drugs

The invention belongs to the field of new application of medicines, and particularly relates to application of 4-hydroxyderrisin in preparation of anti-influenza virus medicines. It is found for the first time that 4-hydroxyderrisin can significantly inhibit replication and internalization of influenza A virus H1N1 and has significant anti-influenza virus activity, the median inhibitory concentrations of 4-hydroxyderrisin in MDCK cells and A549 cells are 0.60 M and 0.23 M respectively, and the 4-hydroxyderrisin is low in cytotoxicity and high in safety. Experiments show that 4-hydroxyderrisin plays a role in the early stage of a virus life replication cycle, and plays an antiviral role by inhibiting virus internalization without affecting virus adsorption and neuraminidase activity. The medicine can be prepared into a solid or solution dosage form, is used for preventing and treating influenza, and has a good application prospect.
Owner:LANZHOU UNIV

Methods of treating cancer using replication stress modulators

An agent that generates DNA replication stress and / or inhibits pathways involved in DNA replication stress tolerance for use in a method of treating a patient with cancer. The treatment comprises: determining whether the cancer expresses HORMAD1; and, if so, administering to said patient an agent that generates DNA replication stress and / or inhibits pathways involved in DNA replication stress tolerance.
Owner:THE INST OF CANCER RES ROYAL CANCER HOSPITAL +2

Intervertebral disc degeneration therapeutic agent containing stem cell-derived extracellular vesicles and method of preparing the same

PendingCN122624528ATissue repairUmbilical cord
The curcumin-coupled copper-gold bimetallic nanoszyme AuCu-Cur prepared by the application can remove ROS and relieve oxidative stress, prevent further damage to DNA, and introduce human umbilical cord mesenchymal stem cell-derived extracellular vesicles (hUCMSC-EVs) to improve the bioavailability. In the system, curcumin can repair damaged DNA by promoting the expression of NEIL3. In addition, the vesicles themselves are rich in various tissue repair-related proteins and RNAs, which can promote DNA replication of notochordal cells (NPCs), reverse the aging state and stimulate extracellular matrix synthesis. In the IVDD model induced by rat tail vertebra puncture, we confirmed that the material has strong antioxidant and DNA repair capacity and can effectively delay cell aging, thereby relieving the progression of IVDD. Compared with existing intervertebral disc biomaterial treatments, the present scheme can realize continuous DNA repair, which is an active, multi-target repair program that not only interrupts the vicious cycle of intervertebral disc degeneration but also promotes tissue transformation to regeneration.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

New application of ginkgetin in treatment of lung cancer

The invention discloses a novel application of ginkgo biflavone in lung cancer treatment, belongs to the technical field of medicines, and researches show that ginkgo biflavone can target CDC7 and is a novel targeted medicine. It is confirmed for the first time that ginkgo biflavone regulates and controls the thermal stability and enzymatic degradation of ginkgo biflavone through targeting CDC7 kinase (binding free energies-8.3 kcal / mol), directly intervenes in the DNA replication process, and provides a natural drug lead compound for development of a novel CDC7 small-molecule inhibitor. The compound has great significance in preventing and treating malignant tumors, and has a wide prospect in the aspect of preparing medicines for treating lung tumors.
Owner:SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE

Comprehensive teaching aid system for genetic science

A comprehensive teaching aid system for genetic science at least including numerous (deoxy-) ribonucleotide models that can be assembled to form DNA / RNA single strands, or to form the beautiful DNA double helix structure when numerous adjacently and oppositely connected deoxynucleotide models are attached by magnets, tRNAs, and three different plates for DNA replication, mRNA transcription and protein synthesis respectively. The (deoxy-) nucleotide model includes a phosphate model, a (deoxy-) ribose model and a base model connected in sequence. Between two adjacently disposed (deoxy-) ribonucleotide models, a (deoxy-) ribose model is connected to a phosphate model in the head-to-tail fashion to form a detachable and flexible chain structure. The base model is laterally connected to the (deoxy-) ribose model, and two base models in two oppositely disposed deoxynucleotide models are flexibly and complementarily attached.
Owner:CHI MAOYEN

Crude cell extract-based high-yield cell-free protein synthesis system and application thereof

The invention discloses a high-yield cell-free protein synthesis system based on a cell crude extract and application of the high-yield cell-free protein synthesis system. The system comprises an escherichia coli extract, a DNA template, a buffer solution, an amino acid mixture, a nucleoside triphosphate mixture, an ATP regeneration system and antibiotics, the antibiotics are selected from compounds having inhibitory activity on metabolic processes except ribosome functions in prokaryotic microorganisms, including but not limited to one or more combinations of interfering DNA replication, DNA transcription, cell wall synthesis, energy metabolism, lipid synthesis or other non-translational related metabolic pathways. According to the method disclosed by the invention, the escherichia coli crude extract is used as a bacterial chassis, and non-essential metabolic pathways in a CFPS system are selectively inhibited by introducing different types of antibiotics, so that the yield of protein synthesis is increased.
Owner:ANYANG INST OF TECH

Hematopoietic stem cell detection method based on e-Y-Click marker

A method for detecting hematopoietic stem cells comprises the steps that a CD133 nucleic acid aptamer functionalized ITO electrode is used as a substrate, e-Y-Click labeling of hematopoietic stem cell surface protein is achieved through in-situ electrochemical activation of PTAD-N3, N3 groups combined on the surface and DBCO modified nucleic acid chains T are subjected to SPAAC reaction, and the hematopoietic stem cells are obtained. The method comprises the following steps of: triggering a self-replication cycle reaction of DNA (Deoxyribose Nucleic Acid), enriching electrochemical signal substances on the surfaces of the hematopoietic stem cells, qualitatively judging the hematopoietic stem cells by detecting electrochemical signals, and correspondingly judging the quantity of the hematopoietic stem cells contained in a sample to be detected according to the established relationship between the intensity of the electrochemical signals and the quantity of the hematopoietic stem cells, so as to realize quantitative detection.
Owner:CHINA STEM CELL GRP SHANGHAI BIOTECHNOLOGY CO LTD +7

Artificial DNA replisome and methods of use thereof

PendingUS20250333714A1Antibody mimetics/scaffoldsHydrolasesDNA replisomeHelicase
Certain embodiments of the invention provide a recombinant polypeptide comprising a T5 DNA polymerase amino acid sequence operably linked to a DNA helicase amino acid sequence, as well as methods of using such a recombinant polypeptide for DNA replication and / or mutagenesis. Certain embodiments of the invention provide a targeted artificial DNA replisome complex. Certain embodiments of the invention provide a targeted DNA mutagenesis system.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA

Use of an antibacterial peptide having antifungal activity

The application relates to the technical field of antibacterial peptides, in particular to application of an antibacterial peptide with antifungal activity, and discloses antifungal activity, antibiofilm activity and an action mechanism of Jelleine-Ic on Candida albicans. Jelleine-Ic shows very strong antifungal activity on Candida albicans. Jelleine-Ic destroys the integrity of the cell wall of Candida albicans and enhances the permeability of the cell membrane of Candida albicans. In addition, Jelleine-Ic interacts with DNA when entering the fungal cell, influences the expression of genes involved in DNA replication and repair, and induces the generation of active oxygen in the cell, thereby accelerating the death of the fungal cell. According to the above results, Jelleine-Ic can effectively inhibit the growth of Candida albicans and has the potential for treating fungal infections.
Owner:ANHUI AGRICULTURAL UNIVERSITY

Traditional Chinese medicine composition for treating gastric cancer and application thereof

The invention relates to a traditional Chinese medicine composition for treating gastric cancer. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 335-415 parts of oldenlandia diffusa, 335-415 parts of solanum septemlobum bunge and 335-415 parts of chinaroot greenbrier. Cell tests prove that the traditional Chinese medicine composition can inhibit the activity of gastric cancer cells, also can significantly inhibit DNA replication activity, and reduces the proliferation and clone formation ability of the gastric cancer cells; protein expression of gastric cancer cell intermediate mesenchymal cell markers N-cadherin and Vimentin, transcription factors Snail and ZEB1 and adhesion factors CD44 and EpCAM is reduced, the EMT process is affected, and then the gastric cancer cell migration and invasion capacity is inhibited. Animal tests prove that the traditional Chinese medicine composition can inhibit tumor growth, shows good anti-gastric cancer activity and has good application prospects.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

E. coli orthogonal DNA replication systems

The present invention provides engineered T7 replisomes that contain one or more modified protein components, and E. coli based orthogonal DNA replication systems that contain such engineered T7 replisomes. Relative to known orthogonal replication systems, the engineered DNA replication systems of the invention are capable of evolving target polynucleotide sequence with enhanced mutation rates.
Owner:THE SCRIPPS RES INST

Crispr-cas9 nickase promotion of cell death

Gene amplifications are an oncogenic driver utilized by many forms of cancer in tumor development or treatment relapse. Promoting genomic instability or the proclivity to propagate genomic alterations through acquired defects in DNA repair machinery, replication licensing, or cell cycle control, gene amplifications not only drive oncogenesis, but also afford an opportunity for therapeutic exploitation. Here, CRISPR-Cas9 nickases are disclosed which selectively promote cancer cell death in a gene amplification-dependent manner. For example, CRISPR- Cas9 nickases generate a lethal number of highly toxic single-ended double-strand breaks within the genome of proliferating cancer cells harboring amplified genomic loci during DNA replication. Cas9 nickases may serve as a tumor-selective therapeutic that mitigates the collateral damage observed with conventional chemoradiotherapies and avoids chemoresistance.
Owner:UNIV OF MASSACHUSETTS

Mutation Sites of SUV420H1 and Its Application in Regulating Tumor Cell Proliferation

The present invention discloses the mutation sites of SUV420H1 and its application in regulating the proliferation of tumor cells. The present invention provides the application of a substance capable of simultaneously site-directed mutating the K219 and R220 sites of the SUV420H1 protein in an organism or cell in any one of the following: inhibiting the proliferation of tumor cells; treating tumors, inhibiting DNA replication in tumor cells; reducing the binding of the SUV420H1 protein and the H2A.Z protein or its nucleosome. The experiments of the present invention prove that the K219R220 site on the SUV420H1 protein, which can affect the binding to H2A.Z, and mutating the K219R220 site on the SUV420H1 protein can inhibit the proliferation of tumor cells, indicating that the K219R220 site on the SUV420H1 protein can be used as a target to study specific drugs for inhibiting the proliferation of tumor cells and has potential clinical application value.
Owner:INSTITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES

Orthogonal DNA replication system

The invention relates to cells, such as bacterial cells, comprising orthogonal DNA replication machinery, linear plasmids that may be replicated by said machinery, uses of said cells and said linear plasmids, methods of maintaining linear plasmids in cells, methods of evolving sequences of interest, and methods of making polypeptides or nucleic acids. Orthogonal systems that are based on or derived from phage, such as phi29, that infect gram-positive bacteria are disclosed herein.
Owner:UNITED KINGDOM RESEARCH AND INNOVATION

Application of 5-fluorodeoxycytidine and medicine

PendingCN120241764AAntibacterial agentsOrganic active ingredientsReplication initiator proteinPharmaceutical drug
The invention discloses application of 5-fluorodeoxycytidine and a medicine, relates to the technical field of biological medicines, and particularly provides application of 5-fluorodeoxycytidine in preparation of a medicine for resisting staphylococcus aureus. The 5-fluorodeoxycytidine can act on staphylococcus aureus to replicate an initiator protein DnaA, inhibit the initiator protein DnaA and cause DNA replication disorder of the staphylococcus aureus, so that the activity of the staphylococcus aureus is effectively inhibited, and a bactericidal effect is achieved.
Owner:SHENZHEN PEOPLES HOSPITAL

Synthesis method of phosphamide ester nucleoside prodrug and drug application

PendingCN118978559ARepair defects that make it difficult to act on target cellsavoid dependenceOrganic active ingredientsSugar derivativesPhosphoramidateNucleoside kinase
The invention discloses a method for synthesizing a phosphoramidate nucleoside prodrug and a drug application of the phosphoramidate nucleoside prodrug, and belongs to the field of organic chemistry. Phosphorus oxychloride, L-alanine isopropyl ester hydrochloride, 2-(hydroxymethyl) phenyl acetate, p-nitrophenol and glucoside are used as raw materials and react under the protection of ultralow-temperature nitrogen, and the nucleoside drug prodrug with biological activity is obtained. According to the invention, the dependence of the drugs on nucleoside kinase is effectively avoided, the metabolic inactivation of phosphohydrolase is resisted, the stability of the drugs is enhanced, the defect that the drugs are difficult to act on target cells due to the ionic characteristics is overcome, and the bioavailability is improved. The phosphamide ester nucleoside prodrug has strong physiological activity on HBV DNA replication, can be further used in potential antiviral drugs, has high inhibition rate on human bladder cancer cells and human lung cancer cells, and can also be further used in anti-cancer drugs.
Owner:HENAN NORMAL UNIV

Enhanced nucleic acid polymerization by the minor groove binding moiety

The present invention relates to methods and compositions for improving nucleic acid polymerization, including DNA replication by in vitro primer extension to generate polymers for use, for example, in DNA template nanopore-based single-molecule sequencing. Nucleic acid polymerase reaction compositions containing polymerization enhancing moieties are provided, which allow for enhancement of DNA polymerase activity with nucleotide analogs, resulting in increased length of primer extension products for sequencing applications.
Owner:F HOFFMANN LA ROCHE & CO AG